Loading
Parathyroid Disorders and Treatments / Ferroptosis and Cancer Prognosis · Journal article
Discover Oncology · August 18, 2026
Raises a question worth testing. It does not answer one.
This is a descriptive, correlative pan-cancer bioinformatic study showing TACSTD2 overexpression across multiple cancers and association with poor prognosis, immune infiltration patterns, and metastasis-related pathways. The findings are exploratory and hypothesis-generating rather than definitive; they suggest TACSTD2 warrants further investigation as a potential biomarker and therapeutic target in TNBC, but do not establish causation or clinical utility.
Pan-cancer bioinformatic analysis with RT-qPCR validation and spatial transcriptomic analysis. Pan-cancer patient cohorts of unspecified size; triple-negative breast cancer cell lines; TNBC patients from spatial transcriptomic dataset. Intervention: No intervention; observational study of TACSTD2 expression and genomic alterations.
TACSTD2 showed widespread overexpression across different cancer types High TACSTD2 expression was notably connected to poor prognosis and genomic instability TACSTD2 expression levels correlated with immune infiltration and distinct immune subtypes
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
These findings are preliminary and should not yet guide clinical practice. TACSTD2 warrants further investigation as a potential prognostic biomarker and therapeutic target in TNBC, but functional validation and prospective clinical studies are needed before biomarker qualification or therapeutic development.
A comprehensive pan-cancer bioinformatic and expression profiling study identifying TACSTD2 as a potential biomarker and therapeutic target, but lacking clinical validation or mechanistic proof of causation.
As stated by the source record.
These findings are preliminary and should not yet guide clinical practice. TACSTD2 warrants further investigation as a potential prognostic biomarker and therapeutic target in TNBC, but functional validation and prospective clinical studies are needed before biomarker qualification or therapeutic development.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Tumor-associated calcium signal transducer 2 ( TACSTD2 ) is widely investigated in cancer research. Its overexpression across multiple cancers is linked to elevated tumor aggressiveness, metastasis, and poor prognosis, making it a potential biomarker for diagnosis, prognosis, and therapy. However, its role has not been explored at the multi-omics pan-cancer level. This study performed a comprehensive pan-cancer analysis to systematically investigate the expression profile, prognostic value, genetic alterations, functional pathways, immune infiltration, and therapeutic relevance of TACSTD2 across multiple cancer types. Besides, RT-qPCR was conducted to assess the expression of TACSTD2 in breast cancer cell lines. TACSTD2 showed widespread overexpression in different cancer types and was notably connected to poor prognosis, genomic instability, and pathways related to metastasis. Its expression levels were also closely correlated with immune infiltration and distinct immune subtypes. In triple-negative breast cancer (TNBC), spatial transcriptomic analysis confirmed that TACSTD2 was mainly expressed in malignant epithelial cells, and high TACSTD2 expression predicted unfavorable survival. Furthermore, RT-qPCR validation confirmed the upregulation of TACSTD2 in TNBC cell lines. Our findings indicate that TACSTD2 is closely associated with tumor progression and tumor microenvironment remodeling, supporting its potential as a biomarker. Importantly, TACSTD2 might represent potential biomarker and candidate target for TNBC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.